{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:12:44Z","timestamp":1774311164239,"version":"3.50.1"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.msard.2021.102929","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T04:02:43Z","timestamp":1616817763000},"page":"102929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update"],"prefix":"10.1016","volume":"51","author":[{"given":"Dominic","family":"Jack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9562-9746","authenticated-orcid":false,"given":"Doris","family":"Damian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Nolting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Galazka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.102929_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102476","article-title":"Normal antibody response after COVID-19 during treatment with cladribine","volume":"46","author":"Celius","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.102929_bib0002","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1177\/1352458520943783","article-title":"COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment","volume":"26","author":"Dersch","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.102929_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102775","article-title":"COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?","volume":"49","author":"Gelibter","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.102929_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102469","article-title":"Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets","volume":"46","author":"Jack","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.102929_bib0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis","author":"Louapre","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2021.102929_bib0006","article-title":"COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience","author":"Preziosa","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.102929_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102800","article-title":"COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review","volume":"50","author":"Sharifian-Dorche","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.102929_bib0008","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1474-4422(20)30147-2","article-title":"An Italian programme for COVID-19 infection in multiple sclerosis","volume":"19","author":"Sormani","year":"2020","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.msard.2021.102929_bib0009","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","article-title":"Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis","volume":"89","author":"Sormani","year":"2021","journal-title":"Ann. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821001966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821001966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:55:38Z","timestamp":1761900938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821001966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":9,"alternative-id":["S2211034821001966"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102929","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102929","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102929"}}